Compare BTQ & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTQ | MYGN |
|---|---|---|
| Founded | 1983 | 1991 |
| Country | Canada | United States |
| Employees | 35 | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.2M | 372.1M |
| IPO Year | N/A | 1996 |
| Metric | BTQ | MYGN |
|---|---|---|
| Price | $2.01 | $5.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $5.98 | $4.11 |
| AVG Volume (30 Days) | 1.6M | ★ 2.7M |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $106.02 | N/A |
| Revenue Next Year | $976.92 | $5.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.82 | $2.74 |
| 52 Week High | $10.20 | $8.50 |
| Indicator | BTQ | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 29.33 | 74.13 |
| Support Level | N/A | $5.57 |
| Resistance Level | $3.40 | $6.34 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | -0.05 | 0.16 |
| Stochastic Oscillator | 12.01 | 92.25 |
BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. The company derives revenue from Software licensing. Geographically, the company has a presence in Canada, Taiwan, Australia, and the United States.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.